{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:36:07Z","timestamp":1790912167702,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1038\/s41375-022-01707-w","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T11:16:20Z","timestamp":1663931780000},"page":"2729-2733","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7343-6214","authenticated-orcid":false,"given":"Warren","family":"Fiskus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9937-0957","authenticated-orcid":false,"given":"Steffen","family":"Boettcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Mill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Birdwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4702-0386","authenticated-orcid":false,"given":"Kaberi","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8027-9659","authenticated-orcid":false,"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Burrows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2621-3584","authenticated-orcid":false,"given":"Joseph D.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-5451","authenticated-orcid":false,"given":"Benjamin L.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5209-5126","authenticated-orcid":false,"given":"Kapil N.","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"1707_CR1","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrc2253","volume":"7","author":"AV Krivtsov","year":"2007","unstructured":"Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7:823\u201333.","journal-title":"Nat Rev Cancer"},{"key":"1707_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-021-01057-7","volume":"14","author":"X Li","year":"2021","unstructured":"Li X, Song Y. Structure, function and inhibition of critical protein-protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins. J Hematol Oncol. 2021;14:56.","journal-title":"J Hematol Oncol"},{"key":"1707_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.molcel.2010.05.011","volume":"38","author":"TA Milne","year":"2010","unstructured":"Milne TA, Kim J, Wang GG, Stadler SC, Basrur V, Whitcomb SJ, et al. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell. 2010;38:853\u201363.","journal-title":"Mol Cell"},{"key":"1707_CR4","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1101\/gad.1619407","volume":"21","author":"B Argiropoulos","year":"2007","unstructured":"Argiropoulos B, Yung E, Humphries RK. Unraveling the crucial roles of Meis1 in leukemogenesis and normal hematopoiesis. Genes Dev. 2007;21:2845\u20139.","journal-title":"Genes Dev"},{"key":"1707_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ccell.2018.08.018","volume":"34","author":"Y Sun","year":"2018","unstructured":"Sun Y, Zhou B, Mao F, Xu J, Miao H, Zou Z, et al. HOXA9 reprograms the enhancer landscape to promote leukemogenesis. Cancer Cell. 2018;34:643\u201358e5.","journal-title":"Cancer Cell"},{"key":"1707_CR6","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1182\/blood.2019004226","volume":"136","author":"B Falini","year":"2020","unstructured":"Falini B, Brunetti L, Sportoletti P, Martelli MP. NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood. 2020;136:1707\u201321.","journal-title":"Blood."},{"key":"1707_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","volume":"34","author":"L Brunetti","year":"2018","unstructured":"Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang YH, Ramabadran R, et al. Mutant NPM1 maintains the leukemic state through HOX expression. Cancer Cell. 2018;34:499\u2013512. e9","journal-title":"Cancer Cell"},{"key":"1707_CR8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1126\/science.aax5863","volume":"367","author":"HJ Uckelmann","year":"2020","unstructured":"Uckelmann HJ, Kim SM, Wong EM, Hatton C, Giovinazzo H, Gadrey JY, et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science. 2020;367:586\u201390.","journal-title":"Science."},{"key":"1707_CR9","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","volume":"36","author":"AV Krivtsov","year":"2019","unstructured":"Krivtsov AV, Evans K, Gadrey JY, Eschle BK, Hatton C, Uckelmann HJ, et al. A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. Cancer Cell. 2019;36:660\u201373. e11","journal-title":"Cancer Cell"},{"key":"1707_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00603-3","volume":"12","author":"W Fiskus","year":"2022","unstructured":"Fiskus W, Boettcher S, Daver N, Mill CP, Sasaki K, Birdwell CE, et al. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 2022;12:5.","journal-title":"Blood Cancer J"},{"key":"1707_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/PPO.0000000000000571","volume":"28","author":"M Swaminathan","year":"2022","unstructured":"Swaminathan M, Bourgeois W, Armstrong SA, Wang ES. Menin inhibitors in acute myeloid leukemia-what does the future hold? Cancer J. 2022;28:62\u201366.","journal-title":"Cancer J"},{"key":"1707_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1126\/science.aax3649","volume":"365","author":"S Boettcher","year":"2019","unstructured":"Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019;365:599\u2013604.","journal-title":"Science."},{"key":"1707_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","volume":"168","author":"JE Bradner","year":"2017","unstructured":"Bradner JE, Hnisz D, Young RA. Transcriptional addiction in cancer. Cell. 2017;168:629\u201343.","journal-title":"Cell."},{"key":"1707_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0165-5","volume":"9","author":"W Fiskus","year":"2019","unstructured":"Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, et al. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019;9:4.","journal-title":"Blood Cancer J"},{"key":"1707_CR15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s43018-022-00366-1","volume":"3","author":"BJ Aubrey","year":"2022","unstructured":"Aubrey BJ, Cutler JA, Bourgeois W, Donovan KA, Gu S, Hatton C, et al. IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. Nat Cancer. 2022;3:595\u2013613.","journal-title":"Nat Cancer"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01707-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01707-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01707-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T18:13:09Z","timestamp":1666894389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01707-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1707"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01707-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"assertion":[{"value":"12 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FB is an employee of Kura Oncology, Inc. BLE has received research funding from Celgene, Deerfield, Novartis, and Calico; and he is a member of the scientific advisory board and shareholder for Neomorph Therapeutics, Skyhawk Therapeutics, and Exo Therapeutics, none of which are directly related to the content of this paper. All other authors declare they have no financial interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}